Načítá se...
Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer
BACKGROUND: The clinical benefit of gemcitabine, the standard systemic therapy of pancreatic cancer (PaCa), remains modest as a result of high chemoresistance. The proteasome inhibitor bortezomib has antitumour activity against PaCa in vitro and in vivo. We examined the antitumour activity of combin...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Blackwell Publishing Ltd
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2785956/ https://ncbi.nlm.nih.gov/pubmed/20495713 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1477-2574.2009.00109.x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|